Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)-Reference-Cited by-同舟云学术

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

Published:2020-02-20 Issue:1 Volume:58 Page:62-79
ISSN:1995-4492
Container-title:Rheumatology Science and Practice
language:
Short-container-title:Naučno-praktičeskaâ revmatologiâ

Author:

Nasonov E. L.¹,Avdeeva A. S.²,Lila A. M.³

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

2. V.A. Nasonova Research Institute of Rheumatology

3. V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Publisher

Mediar Press

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference247 articles.

1. Kubo S, Yamaoka K, Amano K, et al. Discontinuation of tofaci-tinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology (Oxford). 2017;56(8):1293-301. doi: 10.1093/rheumatology/kex068

2. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555

3. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.). doi: 10.14412/1995-4484-2017-409-419

4. Perez-Roman DI, Ortiz-Haro AB, Ruiz-Medrano E, et al. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. RheumatolInt. 2018;38(4):599-606. doi: 10.1007/s00296-017-3910-3

5. Mori S, Ueki Y. Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clin Rheumatol. 2019 Aug 9. doi: 10.1007/s10067-019-04721-z

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a high-performance liquid chromatography with tandem mass spectrometry method for quantification of tofacitinib in human plasma;Drug development & registration;2024-05-28

2. Dynamics of clinical manifestations and cytokine levels in patients with rheumatoid arthritis associated with upadacitinib therapy;HERALD of North-Western State Medical University named after I.I. Mechnikov;2023-12-14

3. Efficacy of tofacitinib in psoriatic arthritis: literature review and case report;Meditsinskiy sovet = Medical Council;2023-11-23

4. The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”;Rheumatology Science and Practice;2023-08-31

5. Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022;Rheumatology Science and Practice;2023-06-28